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A B S T R A C T
Purpose: To describe the experience of ﬁve Israeli pediatric epilepsy clinics treating children and
adolescents diagnosed as having intractable epilepsy with a regimen of medical cannabis oil.
Methods: A retrospective study describing the effect of cannabidiol (CBD)-enriched medical cannabis on
children with epilepsy. The cohort included 74 patients (age range 1–18 years) with intractable epilepsy
resistant to >7 antiepileptic drugs. Forty-nine (66%) also failed a ketogenic diet, vagal nerve stimulator
implantation, or both. They all started medical cannabis oil treatment between 2–11/2014 and were
treated for at least 3 months (average 6 months). The selected formula contained CBD and
tetrahydrocannabinol at a ratio of 20:1 dissolved in olive oil. The CBD dose ranged from 1 to 20 mg/
kg/d. Seizure frequency was assessed by parental report during clinical visits.
Results: CBD treatment yielded a signiﬁcant positive effect on seizure load. Most of the children (66/74,
89%) reported reduction in seizure frequency: 13 (18%) reported 75–100% reduction, 25 (34%) reported
50–75% reduction, 9 (12%) reported 25–50% reduction, and 19 (26%) reported <25% reduction. Five (7%)
patients reported aggravation of seizures which led to CBD withdrawal. In addition, we observed
improvement in behavior and alertness, language, communication, motor skills and sleep. Adverse
reactions included somnolence, fatigue, gastrointestinal disturbances and irritability leading to
withdrawal of cannabis use in 5 patients.
Conclusions: The results of this multicenter study on CBD treatment for intractable epilepsy in a
population of children and adolescents are highly promising. Further prospective, well-designed clinical
trials using enriched CBD medical cannabis are warranted.
 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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About one-third of patients with epilepsy suffer from drug-
resistant disease deﬁned as failure to stop all seizures after an
adequate trial of at least two appropriate medications. The efﬁcacy
of current medications in these cases is limited [1–3]. There is great* Corresponding author at: Pediatric Neurology Unit, Edmond & Lili Safra
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1059-1311/ 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reinterest in the development of new medications which may have
antiepileptic properties, particularly those agents that affect novel
receptors.
The two main cannabis ingredients with central nervous system
(CNS) activity are psychoactiveD9-tetrahydro-cannibinol (THC) and
the non-psychoactive cannabidiol (CBD). THC directly activates the
brain endocannabinoid system, which has a role in synaptic
communication [4]. CBD is a cannabinoid receptor antagonist that
modulates the endogenous cannabinoid system by potentiating
intrinsic anandamide-mediated neurotransmission. In addition,
CBD is involved in the regulation of other cerebral neurotransmitters
and receptors, as well as having an anti-inﬂammatory andserved.
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well understood, but it has become clear that its anticonvulsant
properties do not involve a cannabinoid receptor (CBR)-dependent
mechanism [7]. Because of its multiple targets and high toxicity
threshold, it is currently being investigated as a potentially useful
therapeutic drug in several CNS and extra-CNS disorders, including
epilepsy, in both experimental models and in humans [8,9]. The
effects of cannabis on epilepsy were described by detailed case
reports in the medical literature from as early as the 19th century
[10,11]. Those articles were followed by several epidemiological
studies that claimed a protective effect of marihuana smoking
against seizures [12–14]. CBD was also found to have positive effects
on seizure threshold, severity and lethality in several epilepsy
mouse and rat models [15–18]. Several small controlled studies on
the effect of puriﬁed CBD (200–300 mg/d) on epilepsy in adults were
conducted in the 1970s [19–22]. While the ﬁrst two claimed a
signiﬁcant effect of CBD on seizure frequency, the last two did not
show any beneﬁt for CBD use over placebo. These reported studies
were analyzed in a Cochrane review [23] that concluded that
because of the quality of the studies, the only answered question was
the secondary outcome measure related to adverse effects and
concluded that 200–300 mg/d cannabidiol had been safely admin-
istered to small numbers of patients for short time periods.
The last three years have witnessed growing interest among the
medical community, parent groups and media in the use of
enriched CBD medical cannabis and pure CBD in intractable
pediatric epilepsy. Based on anecdotal reports and parental
pressure, marijuana is currently licensed for seizures or epilepsy
in 14 states in the US [24].
Medical cannabis in various ratios of CBD and THC and in
different preparations (modes of administration) is licensed by the
Israeli Ministry of Health (MOH) for a number of indications,
including oncology-related pain and side effects of chemotherapy,
phantom pain, and pain related to multiple sclerosis, diabetic
neuropathy, spinal cord injury, post-traumatic stress disorder.
severe intractable Gille de la Tourette syndrome, intractable
epilepsy in pediatric and adult patients, intractable Crohn’s disease
and selected cases of severe ﬁbromyalgia. Contraindications for its
administration include a history of drug abuse, signiﬁcant
psychiatric background and congestive heart failure. Only experts
in each speciﬁc ﬁeld are allowed to apply for a license to access a
special unit in the MOH by means of computer-based application
forms. Each application is reviewed, and approval is given for a
period of 6 months to 1 year if considered appropriate by a group of
30 key leaders in these ﬁelds of expertise nominated by the MOH
and signed by one designated MOH expert physician. There are
currently 23,500 active licenses in the MOH registry (200 for
children with epilepsy). The cannabis preparations (oil, cigarettes,
inhalation extract or ﬂowers) are produced by 8 MOH-certiﬁed
growers and distributed by them to the licensed patients through
speciﬁc distribution points and accompanied by personal guidance
for their proper use. Treatment follow-up is performed by the
applying physician.
Our objective in this paper is to present the experience of four
pediatric epilepsy units in Israel that treat children and adolescents
diagnosed as having intractable epilepsy with enriched CBD
medical cannabis.
2. Materials and methods
2.1. Subjects
We conducted a retrospective study based on clinical records of
clinic and phone call visits of children and adolescents with
refractory epilepsy who were being treated in four pediatric
epilepsy centres in Israel. The participating clinics are all tertiaryreferral centers for pediatric epilepsy in Israel, and each treats
thousands of patients with epilepsy, including many with
intractable disease. All the patients that received CBD-enriched
cannabis oil (CECO) were followed by each of the clinics for at least
12 months before receiving CECO. It was offered to them by the
physician after they had been resistant to 5–7 drugs, or treatment
by a ketogenic diet or vagal nerve stimulation (VNS). The
possibility of CECO was also raised by the child’s parents who
learned about that treatment option via information made
available by the media. One pediatric neurologist followed the
patients in each clinic.
The cohort included children who were treated with cannabis
oil for more than 3 months throughout 2014. Patients aged 1–18
years with refractory epilepsy that was characterized by daily
seizures refractory to >7 appropriate antiepileptic drugs (AEDs)
and other treatment modes, i.e., VNS 35/74 (47%), epilepsy surgery
3 (4%), and ketogenic diet 29/74 (39%) were included. Patients with
severe behavioral disorders and signiﬁcant family psychopatholo-
gy were excluded.
The study patients were divided into six groups based on
seizure etiology:
1. Acquired
2. Early epileptic encephalopathy with a known genetic etiology
3. Epileptic encephalopathy without a known genetic etiology
4. Congenital brain malformations
5. Hypoxic ischemic encephalopathy
6. Other (etiology not deﬁned)
2.2. Study medication
CBD-enriched cannabis oil was supplied by two licensed growers
(Better and Tikun Olam, Tel-Aviv, Israel), and the preparation of the
oil was made by two methods. In the ﬁrst method, the cannabis plant
material was extracted in PhEur absolute ethanol, followed by
evaporation and decarboxylation. The concentrate was diluted in
PhEur canola oil to the required concentration of 20% CBD and 1%
THC. Preservatives and antioxidants were added to ensure stability
of the active ingredients. The ingredient concentration and quality
analysis was done four times by high performance liquid
chromatography (HPLC) during the different stages of the prepara-
tion process. In the second method, the cannabis oils were extracted
from two CBD-rich cannabis strains using ethanol as an extracting
solvent. The preparation at the crude extract level, the puriﬁed CBD
and the ﬁnal solution level were analyzed by both HPLC and gas
chromatography-mass spectrometry. The ratio between THC and
CBD was standardized and corrected to 20:1 by the addition of pure
CBD. At the ﬁnal stage, the preparations were assayed to ensure the
absence of fungi and molds (based on the Israeli Standard 885 for
preparation sterility). The CBD and THC analyses were performed in
two independent labs which supply services for the growers. One is a
university lab and the other is a GMP-approved lab.
The CBD dosage ranged from 1 to 20 mg/kg/d, and it was
divided into two groups, 1–10 mg/kg/d and 10–20 mg/kg/d. The
ﬁnal dose used for each patient was deﬁned according to seizure
response and side effects. The THC dosage did not exceed 0.5 mg/
kg/d, which is considered far below the safety margin of THC. In
some cases, the patient’s other medications were reduced if there
was decrease in seizure frequency and adjusted according to side
effects, in addition to drug level adjustments while on CECO.
Seizure reduction was rated according to four levels (0%, <25%, 25–
50%, 50–75%, and 75–100%) as reported by parents and older
patients. Parents were asked to report the number of seizures per
period and we did the percentage calculations. Side effects were
also reviewed.
Table 2
Seizure reduction according to dosage.
Dosage 0% no.
of cases
<25% no.
of cases
25–50%
no. of
cases
50–75%
no. of
cases
>75% no.
of cases
Total no.
of cases
<10 mg/kg/d 4 14 8 24 10 60 (81%)
>10 mg/kg/d 4 5 1 1 3 14 (19%)
Table 3
Adverse events reported in 34/74 patients.
Adverse events No. of cases
Seizure aggravation 13 (18%)
Somnolence/fatigue 16 (22%)
Gastrointestinal problems and irritability 5 (7%)
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3. Results
A total of 74 patients met the study inclusion criteria. One-half
of them (37/74, 50%) were younger than 10 years of age. Sixty-ﬁve
(88%) of the patients were cognitively impaired as follows: mild
16/74 (22%), moderate 14/74 (19%), and severe 34/74 (46%), with
only 10 of them (13%) having normal cognition. The CECO
treatment duration was between 3 and 12 months. The median
duration of exposure was 5.5 months and the duration of follow-up
was 10 months. The CBD dosage ranged from 1 to 20 mg/kg/d: 60
(81%) patients were treated with <10 mg/kg/d of CBD and 14 (19%)
treated with >10 mg/kg/d of CBD, with the highest CBD dose
reaching 270 mg/day.
Most of the patients (66/74, 89%) reported some reduction in
seizure frequency: 13 (18%) had 75–100% reduction, 25 (34%) had
50–75% reduction, 9 (12%) had 25–50% reduction, and 19 (26%) had
<25% reduction. Five (7%) patients reported aggravation of
seizures which led to withdrawal of the cannabis oil.
One patient, a 7-month-old with severe acquired hypoxic
ischemic damage, intractable spasms and partial complex seizures,
became seizure-free on CECO at a dosage of 2 mg/kg/d. The
improvement demonstrated on his electroencephalogram (EEG)
enabled a gradual decrease in the dosages of his other antiepileptic
drugs (AEDs).
The results of cannabis oil treatment according to seizure
etiology are displayed in Table 1. In the ﬁrst two groups (epileptic
encephalopathies with or without known genetic mutations), 66%
(30/45) of the children showed more than a 25% reduction in
seizure frequency, with 23/45 (51%) reporting between 50 and
100% reduction in seizure frequency. Table 2 lists the results of
cannabis oil treatment according to dosage. Positive effects not
related to seizure frequency were reported by 44/74 patients, and
they included improved behavior and alertness in 25/44, improved
language, communication and motor skills in 11/44, and improved
sleep in 8/44.
Adverse events were reported by 34/74 patients (Table 3). The
side effects led to the withdrawal of medical cannabis in ﬁve
patients.
4. Discussion
The use of enriched CBD oil in the treatment for intractable
pediatric epilepsy patients is becoming increasingly popular. Three
publications on retrospective studies appeared between 2013 and
2015 describing parental surveys or the experience of epilepsy
clinics with enriched CBD oil among various pediatric epilepsyTable 1
Results according to seizure etiology.
Seizure reduction
0% no.
of cases
<25% no.
of cases
25–50%
no. of cases
50–75%
no. of cases
>75% no.
of cases
Known genetic
mutation
2 9 2 8 4
Unknown genetic
mutation
0 4 5 8 3
Acquired 1 1 1 2 3
Brain
malformation
0 1 0 1 1
Hypoxic
ischemic
4 1 1 5 0
Others* 1 3 0 1 2
Total 8 (11%) 19 (26%) 9 (12%) 25 (34%) 13 (17%)populations [25–27]. Although they showed a favorable effect of
CBD-enriched cannabis in the pediatric epilepsy population, those
reports lacked objectivity as well as crucial data on the study
population and on the compounds used according to varying
considerations. The ﬁrst was a retrospective study that described a
telephone/Internet survey of 19 parents whose children had
various childhood epileptic encephalopathies for which they
received CBD-enriched medical marijuana: 16 (84%) had a
reduction in seizure frequency and two became seizure-free
[25]. The second report was a retrospective chart review from a
single tertiary epilepsy center, and it included 75 children and
adolescents with various epileptic encephalopathies who were
given medical cannabis [26]. Thirty-three percent reported a >50%
reduction in seizures, while 57% reported some improvement in
seizure control. The response rate was syndrome-dependant:
Dravet syndrome had a rate of 23%, Doose syndrome 0%, and
Lennox–Gastaut syndrome 88.9%. No beneﬁt was demonstrated in
the available EEGs. The third report was an online parental survey
that focused on perceived efﬁcacy, dosage, and tolerability of CBD-
enriched cannabis preparations for children with infantile spasms
and Lennox–Gastaut syndrome and other intractable epilepsies. A
total of 117 parents responded to the survey. The perceived
efﬁcacy and tolerability were similar across etiologic subgroups,
with 85% reporting some reduction in seizure frequency and 14%
reporting complete seizure freedom. The median duration and the
median dosage of CBD exposure were 6.8 months and 4.3 mg/kg/
day, respectively [27]. The few side effects reported in these three
studies included increased appetite, somnolence/fatigue, and an
increase in seizure frequency [25–27]. Rare adverse events were
developmental regression, abnormal movements, status epilepti-
cus requiring intubation, and death. The beneﬁcial effects other
than seizure control that were reported in all three studies by
parents included sleep quality improvement, increased alertness,
and better mood during CBD therapy. Improvements in language
and motor skills were reported in 10% of patients in a study by
Hussain et al. [27].
Our current investigation is a large retrospective study. It differs
from the previously reported studies [25–27] in a number of
aspects. The patients and their epilepsy course were well known to
the treating physicians in all four participating centers. Only two
CBD-enriched cannabis solutions with known and well-controlled
compositions were used, and the titration of dosage was done
regularly by the treating physician according to seizure response
and side effects during clinic visits. The follow-up was done mainly
in person with additional in-between phone calls and not by
printed questionnaires, which may strengthen the reliability of the
data. Because of the novelty of using medical cannabis in pediatric
epilepsy, the physicians were very selective in their inclusion
criteria and chose only patients with severe refractory epilepsy
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ketogenic diet, VNS or epileptic surgery or both).
We divided the patients into six groups according to etiology.
The largest was the group that had epileptic encephalopathy with
or without a known genetic etiology (59%). While 66% of the
epileptic encephalopathy group (30/45) showed more than a 25%
reduction in seizure frequency, only 45% (14/31) of the other
children showed a similar response rate. Importantly, there was no
difference in the baseline severity of epilepsy between the groups
by the physicians’ clinical assessment.
Because of no previous experience and no available data on the
effect and safety of CBD and the limitations related to THC dosage,
three out of the four participating centres chose to titrate the
cannabis oil slowly and kept the patients on a relatively low CBD
dose (<10 mg/kg/d), with only 13 patients (17%) reaching a CECO
dosage higher than 10 mg/kg/d. The small size of the high dose
group precludes our reaching any conclusions regarding dosage-
related efﬁcacy.
Side effects of substance use were inevitable, but their rate and
severity were not different from most known AEDs. There were no
allergic responses. Somnolence and fatigue were relatively
common but they were mostly temporary. It is also important
to mention that CECO was added to at least 2 other AEDs in all
patients, and that drug–drug interactions may have been the
underlying cause for the fatigue and somnolence. There were no
major systemic side effects, and the reported gastrointestinal
problems were of minor signiﬁcance. The seizure aggravation
reported in 7% of the patients can be partly related to the disease’s
natural history. Most of our study patients were cognitively
impaired, thus preventing the option to assess the effect of CECO
on cognition.
Our study has several imitations, including the lack of a control
group, no consistent rate of dosage elevation, reliance upon
parental report on seizure frequency, short duration of the study
and lack of long-term outcome, no EEG results and no measure-
ment of other drug levels. Since it is a retrospective study, there
was no planned baseline period before commencing CECO.
However, because all the patients were well-known and continu-
ously followed-up in the participating clinics, the natural history of
their epilepsy was well known and served as baseline.
5. Conclusions
The results of this multicenter study on CBD enriched cannabis
oil treatment for intractable epilepsy in a population of children
and adolescents are highly promising. Further prospective, well-
designed clinical trials using enriched CBD medical cannabis are
warranted to validate our ﬁndings.
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